RESUMEN
BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) is a syndrome characterized by marked heterogeneity in comorbidities and etiopathology substrates, leading to a diverse range of clinical manifestations and courses. Treatment options have been extremely limited and up to this day, there are virtually no pharmaceutical agents proven to reduce mortality in these patients. OBJECTIVE: The primary objective of this narrative review is to critically summarize existing evidence regarding the use of Angiotensin Receptor-Neprilysin Inhibitor (ARNI), spironolactone, pirfenidone and empagliflozin in HFpEF. METHODS: Medline (via PubMed) and Scopus were searched - from inception up to May 2022- using adequately selected keywords. Additional hand-search was also performed using the references of the articles identified as relevant (snowball strategy). RESULTS: Angiotensin Receptor-Neprilysin Inhibitor (ARNI) and spironolactone, despite being very successful in HFrEF, did not do well in clinical trials of HFpEF, although there appear to be certain subsets of patients who may derive benefit. Data regarding pirfenidone are limited and come from small trials; as a result, it would be premature to draw firm conclusions, although it seems improbable that this agent will ever become a mainstay in the general population of HPpEF patients, while there may be a niche for the drug in individuals with comorbidities associated with an intense fibrotic activity. Finally, empagliflozin, largely welcomed as the first agent to have a "positive" randomized clinical trial in HFpEF, does not seem to evade the general pattern of reduced hospitalizations for HF with no substantial effect on mortality, seen in ARNI and spironolactone HFpEF trials. CONCLUSION: Recent research in drug treatment for HFpEF has resulted in an overall mixed picture, with trials showing potential benefits from certain classes of drugs, such as sodium-glucose co-transporter 2 inhibitors, and no benefit from other drugs, which have shown to be effective in patient with reduced ejection fraction. However, small steps may be the way to go in HFpEF, and success is sometimes just a series of small victories.
RESUMEN
Neurally mediated syncope (NMS) is the most common type of syncope, and head up tilt test (HUTT) is, so far, the most appropriate tool to identify NMS. In this work, an effort to predict the NMS before performing the HUTT is attempted. To achieve this, the heart rate variability (HRV) at rest and during the first minutes of tilting position during HUTT was analyzed using both time and frequency domains. Various features from HRV regularity and complexity, along with wavelet higher-order spectrum (WHOS) analysis in low-frequency (LF) and high-frequency (HF) bands were examined. The experimental results from 26 patients with history of NMS have shown that at rest, a time domain entropy measure and WHOS-based features in LF band exhibit significant differences between positive and negative HUTT as well as among 10 healthy subjects and NMS patients. The best performance of multilayer perceptron neural network (MPNN) was achieved by using an input vector consisted of WHOS-based HRV features in the LF zone and systolic blood pressure from the resting period, yielding an accuracy of 89.7%, assessed by 5-fold cross-validation. The promising results presented here pave the way for an early prediction of the HUTT outcome from resting state, contributing to the identification of patients at higher risk NMS. The HRV analysis along with systolic blood pressure at rest predict NMS using a multilayer perceptron neural network.
